ShareJunction - Stock Forum Messages

Clearbridge Last:0.002 -

SARS RELATED PLAYS..

blink blink 180?

guards80 ( Date: 10-Feb-2020 10:20) Posted:

Yes. Look like boat go up liaoz 😊 😊

OKAYCAN ( Date: 10-Feb-2020 10:18) Posted:

profit taking should be finishing soon i guess

Yes. Look like boat go up liaoz 😊 😊

OKAYCAN ( Date: 10-Feb-2020 10:18) Posted:

profit taking should be finishing soon i guess

Maybe have news? Halt???

Break up 150 . More to go.

Alot taking profit once clear all another up again

trademaster ( Date: 10-Feb-2020 10:00) Posted:

Next wave up. 180?

OKAYCAN ( Date: 10-Feb-2020 09:57) Posted:

wah what is your immediate TP

https://www.trendlines.com/business-units/labs/

Yes

trademaster ( Date: 10-Feb-2020 10:00) Posted:

Next wave up. 180?

OKAYCAN ( Date: 10-Feb-2020 09:57) Posted:

wah what is your immediate TP

Next wave up. 180?

OKAYCAN ( Date: 10-Feb-2020 09:57) Posted:

wah what is your immediate TP?

guards80 ( Date: 10-Feb-2020 09:55) Posted:

Stable liaoz 160 buying support

wah what is your immediate TP?

guards80 ( Date: 10-Feb-2020 09:55) Posted:

Stable liaoz 160 buying support

Any pullback is an opportunity to add more

trademaster ( Date: 10-Feb-2020 09:45) Posted:

clearbridge should be trading raffles medcial px

WBdisciple ( Date: 10-Feb-2020 09:23) Posted:

Clearbridge' s listed associate, Biolidics, is in this field..

How Simple Blood Tests Could Revolutionize Cancer Treatment
The latest DNA science can match tumor types to new treatments, and soon, a blood test might be able to detect early signs of cancer

By detecting the genetic traces of cancer cells in a patient' s blood, medical scientists could open the door to easier diagnosis and more effective treatments. (Guardant Health)
By Sarah Elizabeth Richards
SMITHSONIANMAG.COM
FEBRUARY 7, 2020

When 49-year-old Star Dolbier landed at the University of Maryland Greenebaum Cancer Center in the summer of 2018 with a large mass on her left lung, she&rsquo d done enough research to know the situation was dire. The five-year survival rate for her type of advanced lung cancer&mdash the most common among patients like herself who had never smoked&mdash was 6 percent. Plus, she&rsquo d likely have to go through a painful biopsy surgery&mdash in which doctors remove tissue from her lung through her chest wall&mdash and wait weeks for the results.

So when she met with her new oncologist, Dolbier was surprised to learn that the medical center was part of a research trial that would analyze tiny fragments of cancer DNA that the tumor had shed in her blood. The results of the new test made by a company called Guardant Health in Silicon Valley came back within a week. They revealed that she was part of the 15 percent of lung cancer patients with a mutation in their EGFR gene, which made her eligible for a new drug treatment that been approved just four months earlier for patients with advanced non-small cell lung cancer.

The drug is part of a new generation of targeted therapies that work according to patients&rsquo unique biology. Partially thanks to such drug therapies, the American Cancer Society announced earlier this year the biggest single-year drop in cancer mortality, between 2016 and 2017. In particular, people are dying less from lung cancer, which is the leading cause of cancer deaths and in 2019 killed nearly 143,00 people in the United States.

A year and a half later, Dolbier&rsquo s new drug has kept her cancer at bay.

&ldquo I&rsquo m living a normal life life right now because we were able to find out I had a specific mutation and that there was a specific drug I could take,&rdquo says Dolbier, who lives in Ellicott City, Maryland.

Dolbier is a poster child for the potential of precision medicine in oncology&mdash the rapidly expanding field in which doctors use insights from patients&rsquo DNA to better understand what drives their disease and prescribe personalized drug treatments, rather than resorting to a one-size-fits-all standard of care. Last year saw the approval of more than two dozen such drugs, and over the next two years, analysts predict that the number of new personalized treatments will outnumber those for the general population. As of 2020, there are now targeted therapy drugs for 30 kinds of cancer.

As part of this whirlwind of innovation, more cancer centers are setting up genetic sequencing labs, and more oncologists are advising patients to get their tumor tissue genetically sequenced. Yet scientists are also hoping to learn the deeper secrets of cancer from our blood, which they believe offers more comprehensive information about the complexity of a patient&rsquo s cancer.

&ldquo A tumor might tell you one thing, however not all tumors in the body have the same genetic alterations, and they&rsquo re constantly mutating in response to treatments,&rdquo says Pasi Jä nne, a medical oncologist at Dana-Farber Cancer Institute in Boston. &ldquo Tumors can spit out genetic information into the blood and provide a summary of what&rsquo s happening in the total body in all the different cancers. The direction of where treatment goes might be dictated by that.&rdquo Jä nne explained there are currently five approved precision medicines for genetic subtypes of lung cancer.

&ldquo The existing technology we have available is imaging scans and surgical tissue biopsies. Both are powerful but limited,&rdquo says Viktor Adalsteinsson, associate director of the Gerstner Center for Cancer Diagnostics at the Broad Institute in Cambridge, Massachusetts. &ldquo Imaging can&rsquo t see the smallest cancers and can lead to inconclusive results. Surgical biopsies are invasive and painful and can&rsquo t be done repeatedly throughout care.&rdquo Never mind that up to 30 percent of patients with non-small cell lung cancer don&rsquo t have enough tissue for standard testing, according to a 2018 study in Nature Medicine.

Scientist at Foundation Medicine prepares patient sample for DNA extraction.
Scientist at Foundation Medicine prepares patient sample for DNA extraction. (Foundation Medicine. Inc.)

In addition to identifying patients&rsquo genetic mutations to select treatment, oncologists are looking in their blood post-surgery to see if all the cancer was removed during an operation. &ldquo Traditionally, we have no reliable way of knowing if the surgery got it all,&rdquo Adalsteinsson says. &ldquo This poses a major challenge because we don&rsquo t know which patients have residual cancer could benefit from additional treatment, such as chemotherapy or radiation.&rdquo The new technology aims to identify a returning cancer&rsquo s DNA presence long before a new tumor grows big enough to be seen again on a conventional scan and when treatment is likely to be more effective.

But the biggest advance the field has been waiting for is the ability to detect cancer in the very early stages. If the technology can be developed, a blood test could be part of annual physical exams to tell us when cancer cells first appear in the body, when it&rsquo s most treatable. The 2016 launch of GRAIL, a Silicon Valley startup founded to develop such early-detection technology, was so celebrated that it has raised more than $1.6 billion in venture capital, backed by technology magnates such as Jeff Bezos and Bill Gates.

Although GRAIL&rsquo s first product is still a couple years away from reaching doctors&rsquo offices, more than 50 companies are now working in the so-called &ldquo liquid biopsy&rdquo market that&rsquo s expected to reach $3 billion by 2024. The earliest commercial use of genetic sequencing occurred about a decade ago for what&rsquo s now widely known as the &ldquo non-invasive prenatal test.&rdquo Sequencing machines could analyze fetal DNA in the mother&rsquo s blood and detect a baby&rsquo s risk of Down syndrome in addition to several other genetic disorders as early as nine weeks into a pregnancy. Scientists also discovered the technology could flag maternal cancers.

The Swiss pharmaceutical company Roche was the first to receive FDA approval in 2018 for a liquid biopsy test to identify a lung cancer mutation to select patients for a new drug. Some of the newest entrants are taking advantage of advances in next-generation sequencing to go bigger by looking at many genes and many cancers at once.

In October, Guardant submitted for FDA approval its Guardant360 test that analyzes more than 70 cancer genes to determine treatment, and the company is working on another product for cancer recurrence and last fall launched a study for early detection in colorectal cancer patients. A 2018 JAMA Oncology study of non-small cell lung cancer patients who underwent tissue and blood tests found that the Guardant test picked up important mutations for 82 patients, compared to tissue alone for 47 patients. That same year, Boston-based genomic testing company Foundation Medicine received the FDA&rsquo s &ldquo breakthrough device&rdquo designation to expedite approval of a liquid biopsy test that will analyze 324 genes and biomarkers to inform treatment for metastatic cancer patients.

Scientists at Frederick National Laboratory for Cancer Research in Frederick, Maryland, and Providence St. Joseph Health Molecular Genomics Laboratory in Portland, Oregon, are launching studies on a new test developed by San Diego genetic sequencer manufacturer Illumina that analyzes 523 genes in key cancer-related pathways. And Epic Sciences of San Diego is developing liquid biopsy tests that will track the genetic changes occurring as cancer cells evolve over time. That knowledge would alert oncologists when patients become resistant to particular therapies and should switch treatments.

&ldquo The ability to detect the mechanisms that could lead to resistance may be better in the blood than in tissue. Looking at the blood is a pool of all the metastasized sites,&rdquo says P. Mickey Williams, director of the molecular characterization laboratory at the Frederick National Laboratory for Cancer Research. A 2019 study in Nature Medicine of 42 patients with gastrointestinal cancer found that liquid biopsies were superior in detecting such resistance, when compared to analyzing tissue samples of multiple tumors which had grown genetically diverse in the same patient. The insight, say experts, explains why some patients become resistant to targeted therapies that might have worked beautifully for them in the beginning.

Despite the promise of how liquid biopsies can transform cancer care, some experts say the technology still has some kinks to be worked out, especially when it comes to early detection. For example, not all cancers shed DNA the same way in the blood, and signs of those cancers might be hard to pick up, says Carlo Bifulco, a molecular pathologist at Providence Cancer Institute in Portland, Oregon. The other challenge is that genetic sequencing technology is so sensitive it can identify genetic mutations in healthy people that aren&rsquo t a threat to their health.

&ldquo How many false alarms will happen?&rdquo asks Eric Topol, director of the Scripps Research Translational Institute in La Jolla, California. &ldquo We have so many mutations in our cells, but so few of those become cancer. I don&rsquo t want them to lead to a lot of unnecessary anxiety and big expensive diagnostic evaluations.&rdquo Topol says a more practical approach would use genetic testing to identify patients at high risk and then use blood tests to further screen them. &ldquo People die of cancer when it spreads. If you could get to it in the microscopic stage, well before there was any mass that could be seen by a medical scan, that may well be a great story. But we&rsquo re not there yet.&rdquo

Yet according to GRAIL&rsquo s leadership, we&rsquo re really close&mdash as in only a year or two away. &ldquo We can make a dramatic impact in reducing mortality through early detection,&rdquo says Joshua Ofman, chief medical officer and external affairs. &ldquo Our test was designed to detect any cancer and where in the body it&rsquo s located with a single blood draw,&rdquo he says. &ldquo Our goal was a false-positive rate of less than 1 percent, and we&rsquo ve surpassed that.&rdquo The company is using a technology that looks at methylation&mdash or how genes are expressed&mdash combined with machine-learning algorithms to classify cancer signals from non-cancer ones. The company plans to return recent study results to physicians and patients later this year.

In the meantime, liquid biopsies are already becoming part of mainstream medicine for advanced cancer patients. &ldquo A lot of cancer patients don&rsquo t know there&rsquo s another way to follow their course of cancer. Instead of undergoing an organ biopsy or MRI or CAT scan, you can give a tube of blood,&rdquo Topol says. &ldquo Which would you rather do?&rdquo

added more at 160

guards80 ( Date: 10-Feb-2020 09:45) Posted:

40pips up today

Profits taking for some who missed the boat to buy cheap.

40pips up today

clearbridge should be trading raffles medcial px

WBdisciple ( Date: 10-Feb-2020 09:23) Posted:

Clearbridge' s listed associate, Biolidics, is in this field..

How Simple Blood Tests Could Revolutionize Cancer Treatment
The latest DNA science can match tumor types to new treatments, and soon, a blood test might be able to detect early signs of cancer

By detecting the genetic traces of cancer cells in a patient' s blood, medical scientists could open the door to easier diagnosis and more effective treatments. (Guardant Health)
By Sarah Elizabeth Richards
SMITHSONIANMAG.COM
FEBRUARY 7, 2020

When 49-year-old Star Dolbier landed at the University of Maryland Greenebaum Cancer Center in the summer of 2018 with a large mass on her left lung, she&rsquo d done enough research to know the situation was dire. The five-year survival rate for her type of advanced lung cancer&mdash the most common among patients like herself who had never smoked&mdash was 6 percent. Plus, she&rsquo d likely have to go through a painful biopsy surgery&mdash in which doctors remove tissue from her lung through her chest wall&mdash and wait weeks for the results.

So when she met with her new oncologist, Dolbier was surprised to learn that the medical center was part of a research trial that would analyze tiny fragments of cancer DNA that the tumor had shed in her blood. The results of the new test made by a company called Guardant Health in Silicon Valley came back within a week. They revealed that she was part of the 15 percent of lung cancer patients with a mutation in their EGFR gene, which made her eligible for a new drug treatment that been approved just four months earlier for patients with advanced non-small cell lung cancer.

The drug is part of a new generation of targeted therapies that work according to patients&rsquo unique biology. Partially thanks to such drug therapies, the American Cancer Society announced earlier this year the biggest single-year drop in cancer mortality, between 2016 and 2017. In particular, people are dying less from lung cancer, which is the leading cause of cancer deaths and in 2019 killed nearly 143,00 people in the United States.

A year and a half later, Dolbier&rsquo s new drug has kept her cancer at bay.

&ldquo I&rsquo m living a normal life life right now because we were able to find out I had a specific mutation and that there was a specific drug I could take,&rdquo says Dolbier, who lives in Ellicott City, Maryland.

Dolbier is a poster child for the potential of precision medicine in oncology&mdash the rapidly expanding field in which doctors use insights from patients&rsquo DNA to better understand what drives their disease and prescribe personalized drug treatments, rather than resorting to a one-size-fits-all standard of care. Last year saw the approval of more than two dozen such drugs, and over the next two years, analysts predict that the number of new personalized treatments will outnumber those for the general population. As of 2020, there are now targeted therapy drugs for 30 kinds of cancer.

As part of this whirlwind of innovation, more cancer centers are setting up genetic sequencing labs, and more oncologists are advising patients to get their tumor tissue genetically sequenced. Yet scientists are also hoping to learn the deeper secrets of cancer from our blood, which they believe offers more comprehensive information about the complexity of a patient&rsquo s cancer.

&ldquo A tumor might tell you one thing, however not all tumors in the body have the same genetic alterations, and they&rsquo re constantly mutating in response to treatments,&rdquo says Pasi Jä nne, a medical oncologist at Dana-Farber Cancer Institute in Boston. &ldquo Tumors can spit out genetic information into the blood and provide a summary of what&rsquo s happening in the total body in all the different cancers. The direction of where treatment goes might be dictated by that.&rdquo Jä nne explained there are currently five approved precision medicines for genetic subtypes of lung cancer.

&ldquo The existing technology we have available is imaging scans and surgical tissue biopsies. Both are powerful but limited,&rdquo says Viktor Adalsteinsson, associate director of the Gerstner Center for Cancer Diagnostics at the Broad Institute in Cambridge, Massachusetts. &ldquo Imaging can&rsquo t see the smallest cancers and can lead to inconclusive results. Surgical biopsies are invasive and painful and can&rsquo t be done repeatedly throughout care.&rdquo Never mind that up to 30 percent of patients with non-small cell lung cancer don&rsquo t have enough tissue for standard testing, according to a 2018 study in Nature Medicine.

Scientist at Foundation Medicine prepares patient sample for DNA extraction.
Scientist at Foundation Medicine prepares patient sample for DNA extraction. (Foundation Medicine. Inc.)

In addition to identifying patients&rsquo genetic mutations to select treatment, oncologists are looking in their blood post-surgery to see if all the cancer was removed during an operation. &ldquo Traditionally, we have no reliable way of knowing if the surgery got it all,&rdquo Adalsteinsson says. &ldquo This poses a major challenge because we don&rsquo t know which patients have residual cancer could benefit from additional treatment, such as chemotherapy or radiation.&rdquo The new technology aims to identify a returning cancer&rsquo s DNA presence long before a new tumor grows big enough to be seen again on a conventional scan and when treatment is likely to be more effective.

But the biggest advance the field has been waiting for is the ability to detect cancer in the very early stages. If the technology can be developed, a blood test could be part of annual physical exams to tell us when cancer cells first appear in the body, when it&rsquo s most treatable. The 2016 launch of GRAIL, a Silicon Valley startup founded to develop such early-detection technology, was so celebrated that it has raised more than $1.6 billion in venture capital, backed by technology magnates such as Jeff Bezos and Bill Gates.

Although GRAIL&rsquo s first product is still a couple years away from reaching doctors&rsquo offices, more than 50 companies are now working in the so-called &ldquo liquid biopsy&rdquo market that&rsquo s expected to reach $3 billion by 2024. The earliest commercial use of genetic sequencing occurred about a decade ago for what&rsquo s now widely known as the &ldquo non-invasive prenatal test.&rdquo Sequencing machines could analyze fetal DNA in the mother&rsquo s blood and detect a baby&rsquo s risk of Down syndrome in addition to several other genetic disorders as early as nine weeks into a pregnancy. Scientists also discovered the technology could flag maternal cancers.

The Swiss pharmaceutical company Roche was the first to receive FDA approval in 2018 for a liquid biopsy test to identify a lung cancer mutation to select patients for a new drug. Some of the newest entrants are taking advantage of advances in next-generation sequencing to go bigger by looking at many genes and many cancers at once.

In October, Guardant submitted for FDA approval its Guardant360 test that analyzes more than 70 cancer genes to determine treatment, and the company is working on another product for cancer recurrence and last fall launched a study for early detection in colorectal cancer patients. A 2018 JAMA Oncology study of non-small cell lung cancer patients who underwent tissue and blood tests found that the Guardant test picked up important mutations for 82 patients, compared to tissue alone for 47 patients. That same year, Boston-based genomic testing company Foundation Medicine received the FDA&rsquo s &ldquo breakthrough device&rdquo designation to expedite approval of a liquid biopsy test that will analyze 324 genes and biomarkers to inform treatment for metastatic cancer patients.

Scientists at Frederick National Laboratory for Cancer Research in Frederick, Maryland, and Providence St. Joseph Health Molecular Genomics Laboratory in Portland, Oregon, are launching studies on a new test developed by San Diego genetic sequencer manufacturer Illumina that analyzes 523 genes in key cancer-related pathways. And Epic Sciences of San Diego is developing liquid biopsy tests that will track the genetic changes occurring as cancer cells evolve over time. That knowledge would alert oncologists when patients become resistant to particular therapies and should switch treatments.

&ldquo The ability to detect the mechanisms that could lead to resistance may be better in the blood than in tissue. Looking at the blood is a pool of all the metastasized sites,&rdquo says P. Mickey Williams, director of the molecular characterization laboratory at the Frederick National Laboratory for Cancer Research. A 2019 study in Nature Medicine of 42 patients with gastrointestinal cancer found that liquid biopsies were superior in detecting such resistance, when compared to analyzing tissue samples of multiple tumors which had grown genetically diverse in the same patient. The insight, say experts, explains why some patients become resistant to targeted therapies that might have worked beautifully for them in the beginning.

Despite the promise of how liquid biopsies can transform cancer care, some experts say the technology still has some kinks to be worked out, especially when it comes to early detection. For example, not all cancers shed DNA the same way in the blood, and signs of those cancers might be hard to pick up, says Carlo Bifulco, a molecular pathologist at Providence Cancer Institute in Portland, Oregon. The other challenge is that genetic sequencing technology is so sensitive it can identify genetic mutations in healthy people that aren&rsquo t a threat to their health.

&ldquo How many false alarms will happen?&rdquo asks Eric Topol, director of the Scripps Research Translational Institute in La Jolla, California. &ldquo We have so many mutations in our cells, but so few of those become cancer. I don&rsquo t want them to lead to a lot of unnecessary anxiety and big expensive diagnostic evaluations.&rdquo Topol says a more practical approach would use genetic testing to identify patients at high risk and then use blood tests to further screen them. &ldquo People die of cancer when it spreads. If you could get to it in the microscopic stage, well before there was any mass that could be seen by a medical scan, that may well be a great story. But we&rsquo re not there yet.&rdquo

Yet according to GRAIL&rsquo s leadership, we&rsquo re really close&mdash as in only a year or two away. &ldquo We can make a dramatic impact in reducing mortality through early detection,&rdquo says Joshua Ofman, chief medical officer and external affairs. &ldquo Our test was designed to detect any cancer and where in the body it&rsquo s located with a single blood draw,&rdquo he says. &ldquo Our goal was a false-positive rate of less than 1 percent, and we&rsquo ve surpassed that.&rdquo The company is using a technology that looks at methylation&mdash or how genes are expressed&mdash combined with machine-learning algorithms to classify cancer signals from non-cancer ones. The company plans to return recent study results to physicians and patients later this year.

In the meantime, liquid biopsies are already becoming part of mainstream medicine for advanced cancer patients. &ldquo A lot of cancer patients don&rsquo t know there&rsquo s another way to follow their course of cancer. Instead of undergoing an organ biopsy or MRI or CAT scan, you can give a tube of blood,&rdquo Topol says. &ldquo Which would you rather do?&rdquo

160 easily cleared, next?

guards80 ( Date: 10-Feb-2020 09:42) Posted:

Maybe? Take part in the reserach. See the buy up

easywin ( Date: 10-Feb-2020 09:36) Posted:

Clearbridge found solutions for coronavirus?

Maybe? Take part in the reserach. See the buy up

easywin ( Date: 10-Feb-2020 09:36) Posted:

Clearbridge found solutions for coronavirus?

Buy Biolidics. Specialise in researching. Clearbridge's 24.8% owned Biolidics Limited is a potential multi bagger. In the US, similar companies have captured the attention of pharma giants and have been the subject of several acquisitions over the last two years.

Clearbridge found solutions for coronavirus?

Login Register

SARS RELATED PLAYS..